









市場行情
/
股票
/
nasdaq-urgn
/

Urogen Pharma Ltd

URGN

23.760USD

+0.360+1.54%

收盤 12/24, 13:00（美東）報價延遲15分鐘

1.11B總市值

虧損本益比TTM



Urogen Pharma Ltd

23.760

+0.360+1.54%

概覽公司財務分析

概覽

公司

財務

分析

關於 Urogen Pharma Ltd 公司

UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).

Urogen Pharma Ltd簡介



公司代碼URGN

公司名稱Urogen Pharma Ltd

上市日期May 04, 2017

CEOBarrett (Elizabeth A)

員工數量235

證券類型Ordinary Share

年結日May 04

公司地址9 Ha'ta'asiya St

城市RA'ANANA

上市交易所NASDAQ OMX - NASDAQ BASIC

國家Israel

郵編4365007

電話97297707601

網址https://www.urogen.com/

公司代碼URGN

上市日期May 04, 2017

CEOBarrett (Elizabeth A)

Urogen Pharma Ltd公司高管



名稱

名稱/職務

職務

持股

持股變動

Dr. Arie S. Belldegrun, M.D.

Independent Chairman of the Board

408.69K

Ms. Elizabeth A. (Liz) Barrett

President, Chief Executive Officer, Director

326.69K

Mr. Jason Drew Smith

Chief Compliance Officer, General Counsel, Corporate Secretary

43.30K

+4.37%

Mr. Christopher (Chris) Degnan

Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer

2.28K

Ms. Cynthia M. Butitta

Independent Director

2.00K

Mr. James A. Robinson, Jr.

Independent Director

Dr. Mark P. Schoenberg, M.D.

Chief Medical Officer

Dr. Leana S. Wen, M.D.

Independent Director

Mr. Vincent Perrone

Investor Relations

Mr. Daniel G. Wildman

Independent Director

名稱

名稱/職務

職務

持股

持股變動

Dr. Arie S. Belldegrun, M.D.

Independent Chairman of the Board

408.69K

Ms. Elizabeth A. (Liz) Barrett

President, Chief Executive Officer, Director

326.69K

Mr. Jason Drew Smith

Chief Compliance Officer, General Counsel, Corporate Secretary

43.30K

+4.37%

Mr. Christopher (Chris) Degnan

Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer

2.28K

Ms. Cynthia M. Butitta

Independent Director

2.00K

Mr. James A. Robinson, Jr.

Independent Director

收入明細

單位: USD更新時間: 10月6日週一

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

業務USD

名稱

營收

佔比

Jelmyto

24.21M

0.00%

由於公司未披露，未能獲取相關數據

業務

地區

業務USD

名稱

營收

佔比

Jelmyto

24.21M

0.00%

股東統計

更新時間: 12月2日週二

持股股東

股東類型

持股股東

佔比

RTW Investments L.P.

9.71%

Paradigm BioCapital Advisors LP

9.01%

TD Securities, Inc.

6.82%

Morgan Stanley & Co. LLC

5.25%

Jefferies LLC

4.70%

其他

64.52%

持股股東

佔比

RTW Investments L.P.

9.71%

Paradigm BioCapital Advisors LP

9.01%

TD Securities, Inc.

6.82%

Morgan Stanley & Co. LLC

5.25%

Jefferies LLC

4.70%

其他

64.52%

股東類型

持股股東

佔比

Hedge Fund

29.47%

Research Firm

22.98%

Investment Advisor

19.96%

Investment Advisor/Hedge Fund

19.58%

Insurance Company

4.14%

Venture Capital

3.24%

Individual Investor

2.07%

Corporation

1.79%

Private Equity

1.47%

機構持股



更新時間: 10月1日週三

報告期間

機構數

持股數

持股佔比

持股變動

2025Q3

311

45.66M

97.55%

-6.58M

2025Q2

285

53.00M

114.72%

+5.27M

2025Q1

290

49.25M

108.64%

+1.67M

2024Q4

280

43.94M

103.24%

-1.94M

2024Q3

262

44.13M

104.63%

-2.19M

2024Q2

247

46.02M

111.40%

+11.07M

2024Q1

255

34.96M

99.86%

+5.57M

2023Q4

237

29.16M

94.80%

+4.33M

2023Q3

238

25.93M

86.41%

+2.69M

2023Q2

222

19.52M

83.40%

-392.05K

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

RTW Investments L.P.

4.54M

9.82%

+709.10K

+18.49%

Jun 30, 2025

Paradigm BioCapital Advisors LP

2.33M

5.04%

+2.33M

Aug 05, 2025

TD Securities, Inc.

3.19M

6.9%

+1.44M

+82.40%

Jun 30, 2025

Morgan Stanley & Co. LLC

1.47M

3.19%

+1.27M

+633.13%

Jun 30, 2025

Jefferies LLC

2.20M

4.75%

+1.38M

+169.90%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

2.11M

4.56%

-34.56K

-1.61%

Jun 30, 2025

SilverArc Capital Management, LLC

2.02M

4.37%

+641.32K

+46.43%

Jun 30, 2025

Pontifax Venture Capital

1.49M

3.21%

-1.00

-0.00%

Mar 14, 2024

UBS Asset Management Switzerland AG

1.32M

2.85%

Jan 31, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

ARK Israel Innovative Technology ETF

2.09%

Tema Oncology ETF

1.92%

ALPS Medical Breakthroughs ETF

0.39%

Hypatia Women CEO ETF

0.28%

ProShares Ultra Nasdaq Biotechnology

0.16%

iShares Micro-Cap ETF

0.15%

Fidelity Enhanced Small Cap ETF

0.11%

Vanguard US Momentum Factor ETF

0.1%

Invesco Nasdaq Biotechnology ETF

0.09%

iShares Biotechnology ETF

0.07%

ARK Israel Innovative Technology ETF

佔比2.09%

Tema Oncology ETF

佔比1.92%

ALPS Medical Breakthroughs ETF

佔比0.39%

Hypatia Women CEO ETF

佔比0.28%

ProShares Ultra Nasdaq Biotechnology

佔比0.16%

iShares Micro-Cap ETF

佔比0.15%

Fidelity Enhanced Small Cap ETF

佔比0.11%

Vanguard US Momentum Factor ETF

佔比0.1%

Invesco Nasdaq Biotechnology ETF

佔比0.09%

iShares Biotechnology ETF

佔比0.07%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

常見問題

Urogen Pharma Ltd的前五大股東是誰？



Urogen Pharma Ltd的前五大股東如下：
RTW Investments L.P.
持有股份：4.54M
佔總股份比例：9.82%。
Paradigm BioCapital Advisors LP
持有股份：2.33M
佔總股份比例：5.04%。
TD Securities, Inc.
持有股份：3.19M
佔總股份比例：6.90%。
Morgan Stanley & Co. LLC
持有股份：1.47M
佔總股份比例：3.19%。
Jefferies LLC
持有股份：2.20M
佔總股份比例：4.75%。